Skip to content
Open menu Close menu

Dr Kevin Adams

PositionLecturer in Bioenterprise
Location3.09 ICT building
DepartmentInstitute of Cancer Therapeutics
Telephone+44 (0) 1274 236104
LinkedInVisit my LinkedIn profile

Research Interests (key words only)

Cancer Therapeutics, drug delivery, biomarkers, nanopolymers, entrepreneurship

Teaching and Supervisory Responsibilities

  • Module Leader - Toxicology and Safety Pharmacology (MSc)
  • Module Leader – Enterprise and Commercial Awareness for Scientist (level 2)
  • Module Leader – Entrepreneurial Creativity for Scientist (level 3)
  • Module Leader – Pharmaceutical Product Innovation (MPharm level 4)
  • MSc project supervisor
  • Undergraduate project supervisor (Integrated Science)
  • Personal Tutor - Pharmacy Years 1, 2 and 3

Administrative Responsibilities

  • Project Lead for the business incubation programme that forms a core part of the £12 million DHEZ initiative
  • Chair of Faculty of Life Sciences Regulatory and Quality Systems Committee
  • Pharmacy and Medical Sciences DHEZ working group
  • DHEZ Academic Steering Group
  • Bioscience Business Incubator Management
  • Management Team – Institute of Cancer Therapeutics


I recently returned to Academia (January 2014) after many years working in industry or in commercial roles at the University of Bradford.

My initial laboratory work, during my D.Phil., led to an ongoing involvement in cell culture work with a range of established cell lines and primary cells from animal and human sources. Whilst at Huntingdon Life Science, I was also holder of a Home Office Project Licence with involvement in vivo genetic toxicology, the use of xenograft models and the development of infection models. More recently, I have been involved in projects using human tissue samples for the development of 3D culture models and biomarker studies. In collaboration with Professor Robert Forbes, I have established a pharmaceutics group exploring the physico-chemical properties of anti-cancer agents developed at the Institute of Cancer Therapeutics (and elsewhere) and the use of novel polymers in drug delivery. A first PhD student has recently started with the group and research assistant is currently working on two industrial projects. Related to this, a second collaboration with Dr X Chen is focused on the development of self aggregating nano-polymers and their potential to improve drug delivery. I have been involved in writing several grant applications including a successful Wellcome Trust Translational Award.

Study History

2010             PGCert, Leadership and Management in Higher Education, University of Bradford
1981 - 1985 DPhil, Genetics and Cell Bioogy, University of York.
1979 - 1981 BSc (Hons) Genetics, University of Leeds.
1977 - 1979 University of Aberdeen – transferred to Leeds

Professional History

University of Bradford

  • January 2014-present Lecturer in Bioenterprise, Faculty of Life Sciences
  • January 2012-present (0.2 FTE secondment) Programme Manager, Incanthera Ltd
  • November 2010- Nov 2013 Associate Dean for Employer Engagement, School of Life Sciences
  • Feb 2005 – present BioIncubation Manager, Faculty of Life Sciences

Becton Dickinson

  • August 2002 – August 2004 European Sales and Marketing Manager,BD Biosciences, Becton Dickinson and Company

Huntingdon Life Sciences

  • Nov 1999 –Aug 2002 Business Development Manager (Biosciences)
  • Apr 1998 – Nov 1999 Head of Genetic and Cellular Toxicology
  • Aug 1994 – Apr 1998 Deputy Head of Genetic and Cellular Toxicology
  • Sept 1988 – Aug 1994 Study Director – Genetic Toxicology

University College Swansea

  • 1985 – 1988 Post-doctoral Research Assistant, included 6 months at the Institute for Tumorforschung, University of Essen


Professional Activities

  • Founding member of the UK Bioincubator Forum
  • Member of the Safety Pharmacology Society

Research Areas

Cancer therapeutics, biomarkers, isolation and characterisation of circulating tumour cells and drug delivery

Current Projects

  • Isolation and Characterisation of circulating tumour cells
  • Physico-chemical properties, formulation and parenteral delivery of ICT2588
  • Physico-chemical properties, formulation and parenteral delivery of Es5
  • Soft nano-polymers in drug delivery
  • Water soluble self aggregating nano-polymers
  • Integrin antagonists in cancer treatment

Research Collaborations

  • Prof R Forbes – physico-chemical properties and drug formulation, use of Taylor Dispersion analysis in pharmaceutics (with Malvern Instruments Ltd and Paraytec Ltd)
  • Dr X Chen – self aggregating nano-polymers
  • Incanthera Ltd – ICT2588 and Es5 formulations
  • Kinnactia Ltd – Soft nano-polymers in drug delivery
  • Dr. Mohammed Isreb - microfluidics formulation development and circulating tumour cell isolation


Zaman H, Bright AG, Adams K, Goodall DM, Forbes RT. Characterisation of aggregates of cyclodextrin-drug complexes using Taylor Dispersion Analysis. Int J Pharm. 2017 Apr 30;522(1-2):98-109. doi: 10.1016/j.ijpharm.2017.02.012. Epub 2017 Feb 6. PubMed PMID: 28185958.

Adams K, Martin S. Ethical tissue: a not-for-profit model for human tissue supply. Cell Tissue Bank. 2011 Feb;12(1):9-10. doi: 10.1007/s10561-010-9203-7. Epub 2010 Sep 8.



  • Founder of Ethical Tissue - a licenced research tissue bank based at the University of Bradford. Ethical Tissue was voted UKCTC BioBank of the Year 2016.
  • Founder of Incanthera Ltd - a cancer drug development company with a portfolio of cancer drugs and diagnostics that was spun out from the University of Bradford in 2011.

Share this

Upcoming events

View all events »